Ameeta Kelekar, Ph.D.
Department of Laboratory Medicine and Pathology
Princeton University, 1987, Ph.D.
612-625-3204 - office
612-626-2358 - lab
Mechanisms of Apoptosis
Research in my laboratory focuses on pathways of cell survival and death with special emphasis on Bcl-2 family proteins as regulators of these pathways. Interactions between multi-domain Bcl-2 proteins and members of the BH3-only Bcl-2 family sub-class are pivotal in promoting cell death. Recently, our studies on human BH3-only protein, Noxa, have revealed a post-translational regulatory pathway that suppresses its pro-apoptotic function and imparts to it a novel metabolic and pro-survival role in human hematological malignancies. We are currently investigating the role of this protein and its binding partner, Mcl-1L, in regulating glucose metabolism in leukemia cells. The recognition that cancer cells exhibit altered metabolism and depend heavily on glucose as their major source of energy is leading to novel therapeutic strategies targeted at glycolytic (glucose breakdown) pathways. Major research areas in the laboratory are briefly described below:
Autophagy – its role in cell survival and tumor progression
DNA damaging drugs induce apoptosis via the intrinsic pathway through apoptosome formation and caspase-9 activation. MCF-7 breast cancer cells show little to no caspase-9 activation and a delayed death response response to DNA damaging drugs. Further investigation identified autophagy or “self-consumption” as the underlying mechanism for the delayed apoptotic response. Our studies suggested that reduced autophagy may be an adaptive strategy in immortalized and non-invasive breast tumor cells faced with genotoxic stress and underscored the need for autophagy inhibitors in combination with conventional chemotherapeutic drugs in treating early breast cancers (Abedin et al 2007). We are currently focusing some of our research efforts on the contribution of defective autophagy to tumor initiation and progression in breast cancer.
In collaboration with the group of Dr. S. Ramakrishnan at the University of Minnesota we have investigated the mechanism of action of the angiogenic inhibitor peptides, kringle 5 and endostatin, in human endothelial cells. These studies (Bui-Nguyen et al 2007 and 2009) suggested that both kringle 5 and endostatin induced an apoptotic as well as an autophagic response in endothelial cells, but interfering with the autophagic survival response sensitized cells to the anti-angiogenic effects of the inhibitors by promoting a switch to robust apoptotic cell death.
BH3-only protein, Noxa – its role in apoptosis and glucose metabolism in leukemia cells
We are currently investigating the post-translational regulation of a human BH3-only protein, Noxa, in hematological malignancies. Human Noxa in stably and constitutively expressed in a majority of leukemia cells and kept in check through post-translational control mechanisms. Interaction of Noxa with its pro-survival binding partner Mcl-1L plays a major role in the apoptotic response of proliferating lymphoid and myeloid leukemia cells to glucose deprivation. We show that, in the presence of adequate glucose, human Noxa is phosphorylated on serine13 by the cyclin dependent kinase, Cdk5, and sequestered within large multi-protein cytosolic particles (Lowman et al 2010). Apoptotic triggers, particularly glucose limitation, dephosphorylate Noxa, unmasking its pro-apoptotic function. An understanding of how Noxa is post-translationally regulated will aid in the design of therapeutic strategies that target the modified protein and promote its release from sequestration. Paradoxically, modified sequestered Noxa stimulates glucose consumption and lactate production in T acute lymphocytic leukemia (T-ALL) cells. Our observations point to a novel ‘survival’ role for Noxa in regulating glucose metabolism in cancer cells; specifically our data point to a role for Noxa in the anabolic pentose phosphate pathway that is crucial for dividing cells. Additionally, we have identified the protein components of two Noxa/Mcl-1L-containing complexes from proliferating leukemia cells by mass spectrometry and are currently investigation their function.
Noxa, a canonical tumor suppressor like other BH3-only proteins, had not previously been associated with a survival role. Our studies reveal Noxa as the second BH3-only protein, after family member BAD, to be attributed a metabolic function and underscore the intriguing possibility that other BH3-only members may hold day jobs as pro-survival proteins.
Selected Recent Publications:
- Yan Y., E. A. Hanse, K. Stedman, J. M. Benson, X. H. Lowman, S. Subramanian, A. Kelekar. 2015. Transcription factor C/EBP-b induces tumor suppressor phosphatase PHLPP2 through repression of the miR-17~92 cluster in differentiating AML cells. Cell Death and Differentiation (Epub ahead of print)
- Olenchock B. A., J. Moslehi, A. H. Baik, S. M. Davidson, J. Williams, W. J. Gibson, K. A. Pierce, C. Miller, E. A. Hanse, A. Kelekar, L. B. Sullivan, A. Wagers, C. B. Clish, M. G. Vander Heiden, William G. Kaelin, Jr. 2016. Inhibition of the EglN1 Oxygen Sensor and Rerouting of α-Ketoglutarate are Sufficient for Remote Ischemic Protection. Cell 164:884-895.
- Karim, C. B., L. M. Espinoza-Fonseca, J. Zachary, E. A. Hanse, J. S. Gaynes, D. D. Thomas and A. Kelekar. 2015. Structural Mechanism for Regulation of Bcl-2 protein Noxa by phosphorylation. Scientific Reports. 5: 14557.
- Espinoza-Fonseca, L.M. and A. Kelekar. 2015. High-resolution structural characterization of Noxa, an intrinsically disordered protein, by microsecond molecular dynamics simulations. Molecular BioSystems 11: 1850-1856.
- Das, S. G., D. L. Hermanson, N. Bleeker, X. Lowman, Y. Li, A. Kelekar, C. Xing. 2013. Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) – a novel scaffold that re-sensitizes multidrug resistant leukemia cells to chemotherapy. ACS Chemical Biology 8 (2): 327-335.
- Sanchez, C., P. Perfornis, A. Oskowitz, A. Boonjindasup, D. Cai. S. Dhule. B. Rowan, A. Kelekar, D. Krause, and R. Pochampally. 2011. Activation of autophagy in mesenchymal stem cells provides tumor stromal support. Carcinogenesis 32(7):964-972.
- Lowman X. H., M. A. McDonnell, O. A. Odumade, A. Kosloske, C. Jenness, C. B. Karim, R. Jemmerson, and A. Kelekar. 2010. The Proapoptotic Function of Noxa in Human Leukemia Cells Is Regulated by the Kinase Cdk5 and by Glucose. Molecular Cell, 40 (5): 823-833.
- Preview to Lowman et al article:
Gimenez-Cassina, A and N.N. Danial. 2010. Noxa: a Sweet Twist to Survival and more. Molecular Cell, 40 (5): 687-688.
- Codina, R., A. Vanasse, A. Kelekar, V. Vezys and R. Jemmerson. 2010. Cytochrome c-Induced Lymphocyte Death from the Outside
In: Inhibition by Serum Leucine-Rich Alpha-2-Glycoprotein-1.
Apoptosis, 15: 139-152.
- Kelekar, A. 2008. Edited and Introduced the Review Series
Autophagy in Higher Eukaryotes- A matter of survival or
4 (5): 555 - 556.
- McDonnell, M. A., M. J. Abedin, M. Melendez, T. Platikanova,
J. R. Ecklund, K. Ahmed, and A. Kelekar. 2008. Phosphorylation
of Caspase-9 by Casein Kinase 2 regulates its cleavage by
of Biological Chemistry 283 (29), 20149-20158 (E-pub
ahead of print), May 8, 2008).
- Klionsky, D. et al. 2008. Guidelines for the use and interpretation
of assays for monitoring autophagy in higher eukaryotes. Autophagy,
- Ramakrishnan. S., T. Bui Nguyen, I. V Subramanian and
A. Kelekar. 2007. Autophagy and Angiogenesis - an Addendum. Autophagy. 3:512-515.
- Zhao, Y.B., J. Altman, J.L. Coloff, C.E. Herman, S.R.
Jacobs, H.L. Wieman, J.A. Wofford, L.N. Dimascio, O. Ilkayeva,
A. Kelekar, T. Reya and J.C. Rathmell. 2007. GSK-3 alpha/beta
Mediate a Glucose-Sensitive Anti-Apoptotic Signaling Pathway
to Stabilize Mcl-1. Mol.
Cell. Biol. 27:4328-4339.
- Abedin, M. J, D. Wang, M. A. McDonnell, U. Lehmann, and
A. Kelekar. 2007. Autophagy delays apoptotic death in breast
cancer cells following DNA damage. Cell
Death and Differentiation. 14:500-510;
advance online publication, September 22, 2006; di:10.1038/sj.cdd.4402039.
- Bui-Nguyen, T., I. V Subramanian, A. Kelekar and S. Ramakrishnan.
2007. Angiogenesis Inhibitor, Kringle 5 of human plasminogen,
induces both autophagy and apoptotic death in endothelial
- Goldstein, J. C., C. Muñoz-Pinedo, J-E. Ricci,
S. R. Adams, A. Kelekar, M. Schuler, R. Y. Tsien, and D.
R. Green. 2005. Cytochrome c is released in a single step
during apoptosis. Cell
Death and Differentiation 12, 453-462.
- Ke, H., J. Pei, Z. Ni, H. Xia, H. Qi, T. Woods, A. Kelekar,
and W. Tao. 2004. Putative tumor suppressor LATS2
induces apoptosis through down regulation of Bcl-2 and Bcl-xL.
Experimental Cell Research, 298:329-338. Abstract
- Vallera D. A, N. Jin, Y. Shu, A. Panoskaltsis-Mortari,
A. Kelekar, and W. Chen. 2003. Retroviral immunotoxin gene
therapy of leukemia in mice using leukemia-specific T cells
transduced with an IL-3/Bax hybrid gene. Human
Gene Therapy 4:1787-98.
- McDonnell, M. A., D. Wang, S M. Khan, M. G. Vander Heiden,
and A. Kelekar. 2003. Caspase-9 is activated in a cytochrome
c-independent manner early during TNFa-induced apoptosis
in murine cells. Cell
Death and Differentiation. 10: 1005-1015.
- Kelekar, A. and C. B. Thompson. BH domains. The Encyclopedia
of Molecular Medicine 2001. John Wiley & Sons, New York.,
- Kelekar, A. and C. B. Thompson. Bcl-2 proteins. The Encyclopedia
of Molecular Medicine 2001, John Wiley & Sons, New York,
- Kaspar A. A., S. Okada, J. Kumar, F. R. Poulain, K. A.
Drouvalakis, A. Kelekar, D. A. Hanson, R. M. Kluck, Y. Hitoshi,
D. E. Johnson, C. J. Froelich, C. B. Thompson, D. D. Newmeyer,
A. Anel, C. Clayberger, and A. M. Krensky. 2001. A distinct
pathway of cell-mediated apoptosis initiated by granulysin. J
Immunol. 167: 350-356.
- Kelekar, A., B. S. Chang, M. H. Harris, J. E. Harlan,
S. W. Fesik and C. B. Thompson.1999. The BH3 domain of Bcl-xS
is required for the inhibition of the anti-apoptotic function
of Bcl-xL. Mol.
Cell. Biol. 19: 6673-6681.
- Pena, J. C., A. Kelekar, E. V. Fuchs and C. B. Thompson.
1999. Manipulation of outer root sheath survival perturbs
the hair growth cycle. The
EMBO Journal 18: 3596-3603.
- Minn, A. J., C. S. Kettlun, H. Liang, A. Kelekar, M.
G. Vander Heiden, B. S. Chang, S. W. Fesik, M. Fill and
C. B. Thompson. 1999. Bcl-xL regulates apoptosis by heterodimerization-dependent
and heterodimerization-independent mechanisms. The
EMBO Journal 18: 632-643.
- Kelekar, A., B. S. Chang, J. E. Harlan, S. W. Fesik and
C. B. Thompson. 1997. Bad is a BH3 domain-containing protein
that forms an inactivating dimer with Bcl-xL. Mol.
Cell. Biol. 17: 7040-7046.